Literature DB >> 8803913

The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review.

D J Wallace1.   

Abstract

Chloroquine and hydrocychloroquine have been evaluated in 30 noninfectious disorders and conditions other than rheumatoid arthritis or lupus erythematosus; 12 of these have been subjected to well-designed controlled trials. It is concluded that chloroquines are safe and effective first line therapies for selected patients with porphyria cutanea tarda, cutaneous sarcoidosis, cutaneous manifestations of dermatomyositis, hyperlipidemias and thromboembolic prophylaxis for patients with antiphospholipid antibodies. Published experience with these and other diseases or syndromes are critically reviewed.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8803913

Source DB:  PubMed          Journal:  Lupus        ISSN： 0961-2033            Impact factor:   2.911


  11 in total

Review 1.  Ocular involvement in sarcoidosis.

Authors:  A Rothova
Journal:  Br J Ophthalmol       Date:  2000-01       Impact factor: 4.638

2.  Selective thinning of the perifoveal inner retina as an early sign of hydroxychloroquine retinal toxicity.

Authors:  S Pasadhika; G A Fishman; D Choi; M Shahidi
Journal:  Eye (Lond)       Date:  2010-04-16       Impact factor: 3.775

3.  Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques.

Authors:  Monica Vaccari; Claudio Fenizia; Zhong-Min Ma; Anna Hryniewicz; Adriano Boasso; Melvin N Doster; Christopher J Miller; Niklas Lindegardh; Joel Tarning; Alan L Landay; Gene M Shearer; Genoveffa Franchini
Journal:  AIDS Res Hum Retroviruses       Date:  2013-12-24       Impact factor: 2.205

Review 4.  Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria.

Authors:  Enrique Esteve-Valverde; Alfonso Tapiz-Reula; Domingo Ruiz; Jaume Alijotas-Reig
Journal:  Rheumatol Int       Date:  2019-12-21       Impact factor: 2.631

5.  Randomised controlled trial of weekly chloroquine to re-establish normal erythron iron flux and haemoglobin recovery in postmalarial anaemia.

Authors:  Sharon E Cox; Chidi V Nweneka; Conor P Doherty; Anthony J Fulford; Sophie E Moore; Andrew M Prentice
Journal:  BMJ Open       Date:  2013-07-04       Impact factor: 2.692

Review 6.  Chloroquine-containing compounds: a patent review (2010 - 2014).

Authors:  Paul M Njaria; John Okombo; Nicholas M Njuguna; Kelly Chibale
Journal:  Expert Opin Ther Pat       Date:  2015-06-01       Impact factor: 6.674

Review 7.  Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues.

Authors:  Ashutosh M Shukla; Aparna Wagle Shukla
Journal:  Drugs Context       Date:  2019-11-25

8.  Chloroquine and hydroxychloroquine binding to melanin: Some possible consequences for pathologies.

Authors:  R L Schroeder; J P Gerber
Journal:  Toxicol Rep       Date:  2014-11-04

9.  The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic.

Authors:  Monica Shah; Muskaan Sachdeva; Roni P Dodiuk-Gad
Journal:  Dermatol Ther       Date:  2020-06-05       Impact factor: 3.858

10.  COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study.

Authors:  Roland Derwand; Martin Scholz; Vladimir Zelenko
Journal:  Int J Antimicrob Agents       Date:  2020-10-26       Impact factor: 15.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.